Peer Exchange: Spring 2017 Oncology Stakeholders Summit

An interview with Daryl Pritchard, PhD, vice president for Science Policy at the Personalized Medicine Coalition, on the FDA's drug approval process, developments in the personalized medicine field, and reimbursement models that integrate diagnostics.

An overview of the FDA's Oncology Center of Excellence-a collaborative approach to the clinical approval process.

At the The American Journal of Managed Care®'s Spring 2017 Oncology Stakeholders Summit, the discussion touched off-label communication, the evolving clinical trial design, and healthcare reform, all while ensuring care is patient-centered.

The Institute for Clinical and Economic Review (ICER), has established a robust health technology assessment strategy for engaging patients so that the entire process is informed by the patient experience and what “value” means to them.

It is a fundamental premise that providers and health systems who want to succeed in the existing uncertain healthcare environment must remain focused on delivering value-the highest-quality care at the most efficient price.